China Pharma Holdings Inc Cash Flow Conversion Efficiency
China Pharma Holdings Inc cash flow conversion efficiency. Based on the latest financial reports, China Pharma Holdings Inc (CPHI) has a cash flow conversion efficiency ratio of -0.028x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-236.99K) by net assets ($8.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of China Pharma Holdings Inc (2001–2024)
Cash flow conversion efficiency of China Pharma Holdings Inc from 2001 to 2024. This chart illustrates how China Pharma Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CPHI stock price and chart for real-time trading data and today's change.
China Pharma Holdings Inc Cash Flow Conversion Ratio Explained
China Pharma Holdings Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
China Pharma Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of China Pharma Holdings Inc ranked by their cash flow conversion efficiency. Also see CPHI stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NAYA Biosciences, Inc
NASDAQ:NAYA
|
-0.048x |
|
Kumho Industrial Co Ltd
KO:002995
|
-0.544x |
|
Fjordland Exploration Inc
V:FEX
|
2.832x |
|
Richmond Minerals Inc
V:RMD
|
-0.020x |
|
Halo Technologies Holdings Ltd
AU:HAL
|
0.345x |
|
PolyPlank publ AB
ST:POLY
|
0.323x |
|
Ostrom Climate Solutions Inc
V:COO
|
-0.097x |
|
Scout Security Ltd
AU:SCT
|
-0.203x |
Annual Cash Flow Conversion Efficiency for China Pharma Holdings Inc (2001–2024)
The table below shows the annual cash flow conversion efficiency of China Pharma Holdings Inc from 2001 to 2024. Review CPHI FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $7.75 Million | $-466.36K | -0.060x | +35.87% |
| 2023-12-31 | $7.45 Million | $-699.69K | -0.094x | +1.68% |
| 2022-12-31 | $4.29 Million | $-409.55K | -0.095x | -129.95% |
| 2021-12-31 | $6.02 Million | $-249.84K | -0.042x | -686.36% |
| 2020-12-31 | $8.00 Million | $-42.26K | -0.005x | -108.02% |
| 2019-12-31 | $9.24 Million | $608.31K | 0.066x | +58.21% |
| 2018-12-31 | $30.20 Million | $1.26 Million | 0.042x | +113.12% |
| 2017-12-31 | $43.07 Million | $841.22K | 0.020x | -60.27% |
| 2016-12-31 | $58.91 Million | $2.90 Million | 0.049x | +6.59% |
| 2015-12-31 | $72.64 Million | $3.35 Million | 0.046x | +7.17% |
| 2014-12-31 | $106.25 Million | $4.57 Million | 0.043x | -33.45% |
| 2013-12-31 | $132.94 Million | $8.60 Million | 0.065x | +163.53% |
| 2012-12-31 | $148.52 Million | $3.64 Million | 0.025x | -33.25% |
| 2011-12-31 | $142.48 Million | $5.24 Million | 0.037x | -44.32% |
| 2010-12-31 | $117.94 Million | $7.79 Million | 0.066x | -44.07% |
| 2009-12-31 | $90.40 Million | $10.67 Million | 0.118x | +26.02% |
| 2008-12-31 | $69.87 Million | $6.54 Million | 0.094x | +32.90% |
| 2007-12-31 | $39.76 Million | $2.80 Million | 0.070x | +184.62% |
| 2006-12-31 | $20.85 Million | $-1.74 Million | -0.083x | -115.89% |
| 2005-12-31 | $-68.32K | $-35.81K | 0.524x | 0.00% |
| 2004-12-31 | $-68.32K | $-35.81K | 0.524x | +313.11% |
| 2003-12-31 | $-733.96K | $-93.13K | 0.127x | -75.98% |
| 2002-12-31 | $-566.35K | $-299.20K | 0.528x | 0.00% |
| 2001-12-31 | $-566.35K | $-299.20K | 0.528x | -- |
About China Pharma Holdings Inc
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin inje… Read more